Panamarev, N., Bashmakova, E., Kudryavtsev, A., Chernyaev, D., Mazaev, A., Slepov, E., Zukov, R., & Frank , L. (2023). On the diagnostic and prognostic significance of the oncomarker survivin (BIRC5) in bladder cancer . Voprosy Onkologii, 69(2), 308–315. https://doi.org/10.37469/0507-3758-2023-69-2-308-315

Abstract

Аim. To evaluate the content of survivin in urine as a diagnostic marker for bladder cancer (BC) and to investigate the prognostic value of the rs9904341 (-31G>C) polymorphism in BIRC5 gene promoter in relation to the aggressiveness of BC course among the population of the Krasnoyarsk region.

Materials and methods. The content of survivin was analyzed by immunoassay in 43 urine samples from patients, including 27 with bladder cancer, 4 with other malignant neoplasms, 8 with inflammatory diseases of the urogenital system and benign hyperplasia, and 4 healthy donors. DNA samples from BC patients (285) and healthy donors (183) were genotyped using the previously developed method based on bioluminescence analysis. Quantitative data were compared using the Mann-Whitney U test, and the Pearson χ2 test was used to compare genotype frequencies between BC cases and controls. The association between the polymorphism and BC was evaluated using odds ratios with a 95 % confidence interval, and p < 0.05 was considered significant.

Results. Urine survivin was found to be a parameter capable of defining patients with BC from healthy individuals with a sensitivity of 66.7 % and specificity of 100 %. Elevated levels of survivin were detected in samples from patients with inflammatory diseases and benign hyperplasia of the urinary tract.

It was shown that the -31G>C (rs9904341) polymorphism is not a significant risk factor for the development or recurrence of BC in patients from the Krasnoyarsk region. However, carriage of the GG allele may be a predictor of aggressive disease progression with rapid invasion into the muscular wall of the bladder (48.7 % vs 35.7 %, p = 0.02).

Conclusion. Survivin is a good pre-diagnostic marker for detecting patients with urinary tract diseases: its elevated level in urine may indicate the development of malignant (including BC) and benign hyperplasia, as well as inflammatory diseases of the urothelium. The development of Russian “alarm” urine survivin test for rapid and non-invasive diagnostics is promising. The polymorphism -31G>C (rs9904341) can be considered as a predictor of aggressive course of BC.

https://doi.org/10.37469/0507-3758-2023-69-2-308-315

##article.numberofdownloads## 124

##article.numberofviews## 228

pdf (Русский)

References

Аксель Е.М., Матвеев В.Б. Статистика злокачественных новообразований мочевых и мужских половых органов в России и странах бывшего СССР. Онкоурология. 2019;15(2):15–24 [Axel EM, Matveev VB. Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR. Cancer Urology. 2019;15(2):15–24 (In Russ.]. doi:10.17650/1726-9776-2019-15-2-15-24.

Wheatley SP, Altieri DC. Survivin at a glance. J Cell Sci. 2019;132(7):jcs223826. doi:10.1242/jcs.223826.

Слепов Е.В., Башмакова Е.Е., Панамарев Н.С. и др. Белок сурвивин как перспективный маркер диагностики и лечения злокачественных новообразований. Эффективная фармакотерапия. 2021;17(2):58–63 [Slepov YeV, Bashmakova YeYe, Panamarev NS et al. The Survivin protein as novel anti-cancer diagnosis and treatment marker. Effektivnaya farmakoterapiya. 2021;17(2):58–63 (In Russ.)]. doi:10.33978/2307-3586-2021-17-2-58-63.

Liang Z, Xin R, Yu Y et al. Diagnostic value of urinary survivin as a biomarker for bladder cancer: a systematic review and meta-analysis of published studies. World J Urol. 2018;36(9):1373–1381. doi:10.1007/s00345-018-2285-8.

Xu Y, Fang F, Ludewig G et al. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004;23(7):419–429. doi:10.1089/1044549041474788.

Moazeni-Roodi A, Ghavami S, Hashemi M. Survivin RS9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case-control studies. Int J Clin Oncol. 2019;24(4):335–349. doi:10.1007/s10147-019-01408-y.

Bogdanovic L, Lazic M, Bogdanovic J et al. Polymorphisms of survivin -31 G/C gene are associated with risk of urothelial carcinoma in Serbian population. JBUON. 2017;22(1):270–277.

Башмакова Е.Е., Панамарев Н.С., Кудрявцев А.Н. и др. Анализ связи полиморфизма -31G/С (rs9904341) в гене BIRC5 с риском возникновения рака мочевого пузыря. Сибирский онкологический журнал. 2022;21(4):48–55 [Bashmakova EE, Panamarev NS, Kudryavtsev AN et al. Relationship of -31G/C (rs9904341) polymorphism in the survivin gene BIRC5 and the risk of bladder cancer. Sib J Oncol. 2022;21(4):64–71 (In Russ.)]. doi:10.21294/1814-4861-2022-21-4-48-55

Bashmakova EE, Panamarev NS, Kudryavtsev AN et al. N-extended photoprotein obelin to competitively detect small protein tumor markers. Biochem Biophys Res Commun. 2022;598:69–73. doi:10.1016/j.bbrc.2022.02.011.

Ren YQ, Zhang HY, Su T et al. Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma. Eur Rev Med Pharmacol Sci. 2014;18(20):3063–3068. doi:10.1186/s12957-015-0605-7.

Morgia G, Micali A, Rinaldi M et al. Survivin and NAIP in human benign prostatic hyperplasia: protective role of the association of Serenoa repens, Lycopene and Selenium from the Randomized Clinical Study. Int J Mol Sci. 2017;18(3):680. doi:10.3390/ijms18030680.

Gokmen Karasu AF, Sonmez FC, Aydin S, et al. Survivin expression in simple endometrial polyps and tamoxifen-associated endometrial polyps. Int J Gynecol Pathol. 2018;37(1):27–31. doi:10.1097/PGP.0000000000000376.

Jourabchin A, Mazoochi T, Haddad Kashani H et al. Assessment of relationship between expression of survivin protein and histopathology diagnosis and malignancy severity in colon specimen. J Gastrointest Cancer. 2020;51(1):76–82. doi:10.1007/s12029-019-00206-z.

Ebrahimiyan H, Aslani S, Rezaei N et al. Survivin and autoimmunity; the ins and outs. Immunol. Lett. 2018;193:14–24. doi:10.1016/j.imlet.2017.11.004.

Gong YW, Wang YR, Fan GR et al. Diagnostic and prognostic role of BTA, NMP22, survivin and cytology in urothelial carcinoma. Transl. Cancer Res. 2021;10(7):3192–3205. doi:10.21037/tcr-21-386.

Yahyazadeh R, Bashash D, Ghaffari P et al. Evaluation of hTERT, KRT7, and survivin in urine for noninvasive detection of bladder cancer using real-time PCR. BMC urology. 2021;21(1):64. doi:10.1186/s12894-021-00838-z.

Xu X, Li P, Fu D et al. Combined use of urinary survivin detection and liquid-based cytology for the early diagnosis of bladder urothelial carcinoma. Oncol Lett. 2018;15(5):7739–7743. doi:10.3892/ol.2018.8326.

Li Y, Lu W, Yang J et al. Survivin as a biological biomarker for diagnosis and therapy. Expert Opin Biol Ther. 2021;21(11):1429–1441. doi:10.1080/14712598.2021.1918672.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Ilya Tsimafeyeu , Ruslan Zukov , Vladislav Petkau , Sergey Gamayunov , Irina Plokhotenko , Nikolay Kiselev , Igor Utyashev , Konstantin Gordon , Igor Gulidov, Galina Statsenko , Lyubov Vladimirova, Overall Survival of Patients with Metastatic Esophageal Cancer: Russian Multicenter Registry Study , Voprosy onkologii : Vol. 69 No. 1 (2023)
Ivan Safontsev, Ruslan Zukov, Andrey Modestov, Yevgeniy Slepov, Irina Son, I. Laricheva, ROLE OF SCREENING IN EPIDEMIOLOGY MANAGEMENT FOR LUNG CANCER IN THE KRASNOYARSK REGION , Voprosy onkologii : Vol. 63 No. 3 (2017)